CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals has announced the grant of 200,000 restricted share units (RSUs) and 6,280,000 share options to eligible employees as part of its post-IPO schemes. These grants are designed to align employee interests with company performance and market practices. The RSUs will vest over a four-year period with no performance targets attached.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.